Search results 1-1 of 1 in IgG4-related disease
Results
-
Rochester, Minn.
View Summary
Rituximab in IgG4-Related Disease: A Phase 1-2 Trial
Location:
Rochester, Minn.
Trial status:
Open for Enrollment
Why is this study being done?
This two-center trial will enroll at total of 30 patients with IgG4-RD. The two participating sites are the Massachusetts General Hospital (Boston, MA) and the Mayo Clinic (Rochester, MN). All patients will receive rituximab 1 gram intravenously times two doses, separated by approximately 15 days. The primary efficacy outcome - disease remission and successful completion of the glucocorticoid taper - will be assessed at six months. Patients will be followed on the protocol for an additional six months after measurement of the primary outcome.
NCT ID:
NCT01584388
Who can I contact for additional information about this study?
Rochester: Mark Topazian, MD 507-284-7602
Lori A Bergstrom, RN 507-538-1887